Vimarsana
Biggest News Aggregation in the World

Page 2 - Brent Ness News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Brent Ness. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Brent Ness Today - Breaking & Trending Today

Aclarion Adds to Growing Key Opinion Leader Program with - Vimarsana News

Aclarion Adds to Growing Key Opinion Leader Program with

Dr. Uribe is the fourth national KOL to join the Aclarion team this year.  Development of this program supports Aclarion’s commitment to lead with strong...

Aclarion Adds to Strong Patent Portfolio with Notice of - Vimarsana News

Aclarion Adds to Strong Patent Portfolio with Notice of

Strengthens portfolio by addressing the anaerobic bacteria that can seed into the intervertebral disc, proliferate, and accelerate painful disc...

Aclarion Inc.: Dr. Sigurd Berven to join Aclarion as a Key Opinion Leader Surgeon Advisor - Vimarsana News

Aclarion Inc.: Dr. Sigurd Berven to join Aclarion as a Key Opinion Leader Surgeon Advisor

BROOMFIELD, CO / ACCESSWIRE / October 24, 2022 / Aclarion, Inc., ("Aclarion" or the "Company") (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented

Dr. Sigurd Berven to join Aclarion as a Key Opinion Leader Surgeon Advisor - Vimarsana News

Dr. Sigurd Berven to join Aclarion as a Key Opinion Leader Surgeon Advisor

Dr. Sigurd Berven to join Aclarion as a Key Opinion Leader Surgeon Advisor - read this article along with other careers information, tips and advice on BioSpace

The Investor Summit: Aclarion, Inc. to Present at Investor Summit Group's Q3 Virtual Conference - Vimarsana News

The Investor Summit: Aclarion, Inc. to Present at Investor Summit Group's Q3 Virtual Conference

Broomfield, Colorado--(Newsfile Corp. - August 4, 2022) - Aclarion, Inc. (NASDAQ: ACON) (NASDAQ: ACONW) ("Aclarion" or the "Company"), a healthcare technology company that is leveraging biomarkers and